- Hikma Pharmaceuticals
- 08 August 2024 09:01:52
Source: Sharecast
Hikma said statutory operating profits had grown 43% to $351.0m, with revenues up 10% on a statutory basis at $1.56bn and basic earnings per share surging 81% to $1.02 each.
Cashflow from operating activities, however, was down 11% at $198.0m.
Hikma now expects group revenue to grow in the range of 6-8% in FY24, up from previous guidance of 4-6%, while core operating profits were pegged to come in between $700.0m and $730.0m, up from previous guidance of $660.0m to $700.0m.
Chief executive Riad Mishlawi said: "We had an excellent first half of the year. All of our businesses contributed to our strong performance, delivering 10% group revenue growth.
"The outlook for 2024 remains strong and we are pleased to upgrade group revenue and profit guidance."
As of 0900 BST, Hikma shares were up 7.99% at 1,987.00p.
Reporting by Iain Gilbert at Sharecast.com